Attached files

file filename
EX-99 - EXHIBIT 99.1 - ClearPoint Neuro, Inc.mrii20130508_8kex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  


  

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

  

Date of ReportMay 9, 2013

(Date of earliest event reported)

  

MRI INTERVENTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 

000-54575

58-2394628

(State or other jurisdiction 

(Commission File

(I.R.S. Employer

of incorporation or organization)

Number)

Identification No.)

One Commerce Square, Suite 2550   
Memphis, Tennessee 38103
(Address of principal executive offices) (Zip Code)

 

(901) 522-9300

(Registrant's telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 2.02. Results of Operations and Financial Condition.


On May 9, 2013, MRI Interventions, Inc. (the “Company”) issued a press release announcing information regarding the Company’s results of operations and financial condition for the first fiscal quarter ended March 31, 2013. A copy of the press release is furnished herewith as Exhibit 99.1.


The press release is furnished by the Company pursuant to Item 2.02 of Form 8-K and will not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

Item 7.01. Regulation FD Disclosure.


The Company sold 70 SmartFrame kits during the three months ended March 31, 2013. For the six month period ended December 31, 2012, the Company sold a total of 118 SmartFrame kits. The SmartFrame targeting device is an MRI-compatible trajectory frame that serves as the centerpiece of the ClearPoint system’s disposable components. Depending on the type of neurological procedure being performed, a ClearPoint procedure will utilize either one or two SmartFrame kits.

 

This information is furnished by the Company pursuant to Item 7.01 of Form 8-K and will not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.



Item 9.01. Financial Statements and Exhibits.


(d)

Exhibits.

 

See Exhibit Index immediately following signature page.


 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MRI INTERVENTIONS, INC.

 
       
        
  By: /s/ Oscar L. Thomas  
    Oscar L. Thomas  
    Vice President, Business Affairs  

 

Date:     May 9, 2013

 

 
3

 

 

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press Release of the Company dated May 9, 2013

 

 

 

 4